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FSHD is linked to the misexpression of the DUX4 gene contained within the D4Z4 repeat array 
on chromosome 4. The gene encodes the DUX4 protein, a cytotoxic transcription factor that 
presumably causes the symptoms of the disease. However, individuals have been identified 
who express DUX4 in their muscle biopsies, but who remain asymptomatic, suggesting that 
there are other factors that modify FSHD penetrance or severity. We hypothesized that an 
FSHD-modifying factor would physically interact with DUX4, and we took a proteomic approach 
to identify DUX4-interacting proteins. We identified the multifunctional C1QBP protein as one 
such factor. C1QBP is known to regulate several processes that DUX4 affects, including gene 
expression, oxidative stress, apoptosis, and pre-mRNA splicing. We used siC1QBP knockdown 
assays to determine if C1QBP affects DUX4 activity. While C1QBP had little effect on DUX4 
activity in myotubes, we found that it inhibits the kinetics of DUX4-target gene activation during 
myogenic differentiation. This identifies C1QBP as a regulator of DUX4 activity and a potential 
target for FSHD therapeutics. Importantly, C1QBP is regulated by binding to the signaling 
molecule hyaluronic acid (HA). Decreasing HA by treating cells with 4-methylumbelliferone 
(4MU), an inhibitor of HA synthesis, resulted in a sharp decline in DUX4 activity and also greatly 
reduced its cytotoxicity. We have found that DUX4-induced cytotoxicity is associated with 
severe mislocalizaton of C1QBP, which is prevented by 4MU. This defect is not a downstream 
result of DUX4-induced oxidative stress, as it could not be prevented by treating cells with an 
antioxidant, nor could it be recapitulated by exposing cells to oxidants. This identifies C1QBP as 
a target for the treatment of FSHD, and in particular indicates that 4MU, already an approved 
drug in Europe and currently under investigation for other indications, may be an effective 
C1QBP-targeting FSHD therapeutic compound. 
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